Precision biosciences inc stock.

Nov 6, 2023 · Precision BioSciences Inc, a biotechnology company, has been attracting attention from investors due to its potential for growth. On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value.

Precision biosciences inc stock. Things To Know About Precision biosciences inc stock.

Medicure Inc has a Value Score of 85, which is considered to be undervalued. Medicure Inc’s price-earnings ratio is 7.5 compared to the industry median at 21.6. This means that it has a lower price relative to its earnings compared to its peers. This makes Medicure Inc more attractive for value investors.Nov 24, 2023 · Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the fir... Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company...DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...

In June 2022, Precision announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total net proceeds of approximately $46.7 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life ... risks related to ownership of our common stock; ...Jun 21, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately ...

Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) Simply Wall St. August 6, 2023 at 5:03 AM · 2 min read. Celebrations may be in order for Precision ...

DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the closing of its initial public offering of 9,085,000 shares of common stock, which includes the full exercise of …Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. ... as well as an equity investment by Lilly of $35 million in Precision's ...The largest individual shareholder of Apple, Inc. is Arthur D. Levinson, with over 1.1 million shares, as of late November 2014. Levinson is currently the non-executive Chairman of the Board of directors for Apple. He joined the Board in 20...Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More.

The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ...

EVLO: Get the latest Evelo Biosciences stock price and detailed information including EVLO news, historical charts and realtime prices. Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% ...

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Precision BioSciences, Inc. : DTIL Stock Price | US74019P1084 | MarketScreener. Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 …LOS ANGELES, May 10, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined ...Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...On November 6, 2023, the stock price of Precision BioSciences Inc, ticker symbol DTIL, was at 0.41. However, according to data from CNN Money, analysts are predicting a significant increase in the stock’s value. Four analysts have offered 12-month price forecasts for Precision BioSciences Inc, with a median target of 3.00.EVLO: Get the latest Evelo Biosciences stock price and detailed information including EVLO news, historical charts and realtime prices. Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% ...

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the Company’s President …WebBMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT. HC Wainwright Lowers Price Target on Precision BioSciences to $17 from $20, Keeps Buy Rating. Nov. 10. MT. SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company …Corporate Profile Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …Precision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the companyPrecision BioSciences has inked an approximately up-to-$1.5 billion in vivo gene editing R&D collaboration and license agreement with Novartis aimed at helping it develop one-time treatments for ...DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...

DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ...Tesla’s stock is predicted to increase in value in 2015, according to Forbes. In January 2015, Forbes noted that Tesla Motors, Inc.

Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...WebNov 24, 2023 · Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program.PBGENE-HBV is designed to potentially eliminate hepatitis B …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including ...About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.

Get Our Latest Stock Report on Precision BioSciences. Precision BioSciences Stock Performance. NASDAQ:DTIL traded up $0.01 during trading on Monday, reaching $0.38. The company’s stock had a ...Web

Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish …WebA high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis. Yu: Precision BioSciences: Current Employment, Current equity holder in publicly-traded company. Heery: Precision BioSciences: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Arcellx: Current Employment, Current holder of stock options in a privately-held company.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an …WebPrecision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in …Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate …Precision's platform and products are protected by a comprehensive portfolio including more than 80 patents to date. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a …Precision BioSciences to Report Third Quarter Results on November 7, 2023. DURHAM, N.C., November 01, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish ... May 9, 2023 · Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ... DTIL | Complete Precision Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and …Nov 24, 2023 · Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Instagram:https://instagram. market index definitionorc nyseforex vps serverhigher dividend Nov 29, 2023 · View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary … ishares national muni bond etfuaw strike update list Jun 20, 2023 · Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares. fpe stock Nov 17, 2023 · In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ... DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish financial results for the third quarter 2023 and provide a ...